One formula, torn down — the design choices, the chemistry, and the details that matter at the bench.
Your trusted source for compounding pharmacy education, news and insights.
The committee recommended both forms of Epitalon and Semax for the 503A list today — and voted against Emideltide (DSIP). DSIP is the first substance across both days where PCAC sided with FDA staff.
The committee recommended BPC-157, KPV, TB-500, and MOTS-c for the 503A bulk list.
Extended BUDs aren't just for patient safety. They can improve your operations and bottom line.
Three USP <797> Category 3 studies. $4,000/year. Limited to 20 pharmacies.
One formula, broken down: the decisions behind the spec sheet.
